Search Results

There are 13602 results for: content related to: Tolvaptan and hyponatremia in a patient with cirrhosis

  1. You have free access to this content
    Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 73, Issue 4, April 2012, Pages: 579–587, Susan E. Shoaf, Patricia Bricmont and Suresh Mallikaarjun

    Version of Record online : 12 MAR 2012, DOI: 10.1111/j.1365-2125.2011.04114.x

  2. In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2011, Pages: 761–769, Dr Susan E. Shoaf, Mr Yoshihiro Ohzone, Dr Shin-ichi Ninomiya, Dr Masayuki Furukawa, Dr Patricia Bricmont, Dr Eiji Kashiyama and Dr Suresh Mallikaarjun

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010376193

  3. Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 47, Issue 12, December 2007, Pages: 1498–1507, Susa E. Shoaf, Zhao Wang, Patricia Bricmont and Suresh Mallikaarjun

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007307877

  4. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: A randomized, double-blind, placebo-controlled trial

    Hepatology Research

    Volume 44, Issue 1, January 2014, Pages: 83–91, Kiwamu Okita, Seiji Kawazoe, Chitomi Hasebe, Kozo Kajimura, Akira Kaneko, Mitsuru Okada, Isao Sakaida and ASCITES Dose-Finding Trial Group

    Version of Record online : 26 MAR 2013, DOI: 10.1111/hepr.12099

  5. Current Therapeutic Options for Hyponatremia: Indications, Limitations, and Confounding Variables

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 5P2, May 2011, Pages: 18S–24S, Theresa Human

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.5.18S

  6. Hyponatremia in cirrhosis

    Journal of Hospital Medicine

    Volume 7, Issue S4, April 2012, Pages: S14–S17, Samuel H. Sigal

    Version of Record online : 6 APR 2012, DOI: 10.1002/jhm.1915

  7. You have free access to this content
    Abstracts

    European Journal of Heart Failure

    Volume 17, Issue S1, May 2015, Pages: 5–441,

    Version of Record online : 22 MAY 2015, DOI: 10.1002/ejhf.277

  8. You have free access to this content
    Hyponatremia in Acute Decompensated Heart Failure: Mechanisms, Prognosis, and Treatment Options

    Clinical Cardiology

    Volume 33, Issue 11, November 2010, Pages: 666–671, Geoffrey T. Jao and Jun R. Chiong

    Version of Record online : 18 NOV 2010, DOI: 10.1002/clc.20822

  9. You have free access to this content
    Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions

    Journal of Clinical Pharmacy and Therapeutics

    Volume 40, Issue 4, August 2015, Pages: 376–385, C. Urso, S. Brucculeri and G. Caimi

    Version of Record online : 29 APR 2015, DOI: 10.1111/jcpt.12279

  10. You have free access to this content
    Tolvaptan, an Orally Active Vasopressin V2-Receptor Antagonist—Pharmacology and Clinical Trials

    Cardiovascular Drug Reviews

    Volume 25, Issue 1, Spring 2007, Pages: 1–13, Toshiki Miyazaki, Hiroyuki Fujiki, Yoshitaka Yamamura, Shigeki Nakamura and Toyoki Mori

    Version of Record online : 13 APR 2007, DOI: 10.1111/j.1527-3466.2007.00001.x

  11. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial

    Hepatology Research

    Volume 44, Issue 1, January 2014, Pages: 73–82, Isao Sakaida, Seiji Kawazoe, Kozo Kajimura, Takafumi Saito, Chiaki Okuse, Koichi Takaguchi, Mitsuru Okada, Kiwamu Okita and for the ASCITES-DOUBLEBLIND Study Group

    Version of Record online : 2 APR 2013, DOI: 10.1111/hepr.12098

  12. Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan and Warfarin in Healthy Subjects

    Clinical Pharmacology in Drug Development

    Volume 1, Issue 2, April 2012, Pages: 67–75, Susan E. Shoaf and Suresh Mallikaarjun

    Version of Record online : 10 JAN 2013, DOI: 10.1177/2160763X12439702

  13. Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate

    Pediatrics International

    Volume 57, Issue 5, October 2015, Pages: 1020–1022, Nikiko Sato, Tokio Sugiura, Rika Nagasaki, Kazutaka Suzuki, Koichi Ito, Takenori Kato, Sachiko Inukai and Shinji Saitoh

    Version of Record online : 10 SEP 2015, DOI: 10.1111/ped.12697

  14. You have free access to this content
    Novel additional indication of tolvaptan: Can tolvaptan provide a beneficial therapeutic option in cirrhotic patients with ascites?

    Hepatology Research

    Volume 44, Issue 1, January 2014, Pages: 70–72, Toru Ishikawa

    Version of Record online : 5 JAN 2014, DOI: 10.1111/hepr.12137

  15. The Role of Vasopressin and Vasopressin Antagonists in Heart Failure

    Heart Failure: Pharmacologic Management

    Olaf Hedrich, Marvin A. Konstam, James Eric Udelson, Pages: 187–204, 2007

    Published Online : 16 NOV 2007, DOI: 10.1002/9780470994740.ch13

  16. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis

    Biopharmaceutics & Drug Disposition

    Volume 34, Issue 6, September 2013, Pages: 336–347, Scott A. Van Wart, Susan E. Shoaf, Suresh Mallikaarjun and Donald E. Mager

    Version of Record online : 6 AUG 2013, DOI: 10.1002/bdd.1849

  17. You have free access to this content
    Tolvaptan in hospitalized cancer patients with hyponatremia: A double-blind, randomized, placebo-controlled clinical trial on efficacy and safety

    Cancer

    Volume 120, Issue 5, 1 March 2014, Pages: 744–751, Abdulla K. Salahudeen, Najeeba Ali, Marina George, Amit Lahoti and Shana Palla

    Version of Record online : 5 NOV 2013, DOI: 10.1002/cncr.28468

  18. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study

    Cardiovascular Therapeutics

    Volume 33, Issue 5, October 2015, Pages: 275–281, Toshitaka Okabe, Tadayuki Yakushiji, Wataru Igawa, Morio Ono, Takehiko Kido, Seitaro Ebara, Kennosuke Yamashita, Myong Hwa Yamamoto, Shigeo Saito, Koichi Hoshimoto, Kisaki Amemiya, Naoei Isomura, Hiroshi Araki and Masahiko Ochiai

    Version of Record online : 11 SEP 2015, DOI: 10.1111/1755-5922.12142

  19. You have free access to this content
    Abstracts

    European Journal of Heart Failure

    Volume 18, Issue S1, May 2016, Pages: 8–521,

    Version of Record online : 24 MAY 2016, DOI: 10.1002/ejhf.539

  20. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH

    The Journal of Clinical Pharmacology

    Volume 54, Issue 12, December 2014, Pages: 1362–1367, Shi Chen, Jia-Jun Zhao, Nan-Wei Tong, Xiao-Hui Guo, Ming-Cai Qiu, Gang-Yi Yang, Zhi-Min Liu, Jian-Hua Ma, Zhen-Wen Zhang and Feng Gu

    Version of Record online : 12 NOV 2014, DOI: 10.1002/jcph.342